RELAPSED NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Targeting CAR t therapy aims to outperform standard treatment in lymphoma
Disease control Recruiting nowThis study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
New CAR T-Cell therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
Double-Pronged attack: new cell therapy targets tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. The therapy uses a patient's own immune cells, which are modified to recognize and attack two markers on cancer cells …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
Immune cell boost may shield kids from Post-Transplant infections
Disease control Recruiting nowThis study tests whether adding a special type of immune cell (memory T cells) after a donor stem cell transplant can help prevent serious viral and fungal infections. It involves up to 100 children and young adults with blood cancers or immune disorders. The approach aims to spe…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Double-Targeted immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests whether giving a special immune cell treatment (CAR-T therapy) followed by two additional drugs (mosunetuzumab and polatuzumab) can shrink tumors in people with aggressive non-Hodgkin lymphoma that has returned or not responded to prior treatments. About 22 adult…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy offers hope for relapsed lymphoma patients
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. About 24 participants will receive the treatment …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Radiation boost may help CAR-T therapy fight stubborn lymphoma
Disease control Recruiting nowThis study tests whether giving focused radiation to large tumors before CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 participants will receive the radiation followed by standar…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New CAR T-Cell therapy trial offers hope for tough blood cancers
Disease control Recruiting nowThis study tests a personalized treatment using a patient's own immune cells, modified to target and attack cancer cells. It is for people with aggressive lymphoma or acute lymphoblastic leukemia that has come back or not responded to standard treatments. The goal is to find the …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug aims to tame CAR-T Therapy's dangerous side effects
Disease control Recruiting nowThis study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC